StockData
Decoy Therapeutics Inc. logo

Decoy Therapeutics Inc. (DCOY) stock

DCOYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$0.87−0.01 (-1.13%)

Close on Nov 19, 2026Market cap $570.08KP/E –Yield –

Decoy Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Decoy Therapeutics's free cash flow for the twelve months ending Dec 31, 2018 was $4.18M. For fiscal 2025 it was -$5.40M. The highest annual figure on record is $4.18M in fiscal 2018.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$5.40M–
FY2024Dec 31, 2024-$4.53M–
FY2021Dec 31, 2021-$10.20M–
FY2020Dec 31, 2020-$10.31M–
FY2019Dec 31, 2019-$11.58M-377.2%
FY2018Dec 31, 2018$4.18M–
FY2017Dec 31, 2017-$27.84M–
FY2016Dec 31, 2016-$32.61M–
FY2015Dec 31, 2015-$21.01M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2018Dec 31, 2018$387.54K–
Q3 FY2018Sep 30, 2018$21.46M–
Q2 FY2018Jun 30, 2018-$8.26M–
Q1 FY2018Mar 31, 2018-$9.41M–
Q4 FY2017Dec 31, 2017-$5.77M–
Q3 FY2017Sep 30, 2017-$8.10M–
Q2 FY2017Jun 30, 2017-$5.72M–
Q1 FY2017Mar 31, 2017-$8.25M–
Q4 FY2016Dec 31, 2016-$6.35M–
Q3 FY2016Sep 30, 2016-$7.47M–

More Decoy Therapeutics figures

See a number that looks wrong?